title: Effects of zolmitriptan (Zomig) on central serotonergic neurotransmission as assessed by active oddball auditory event-related potentials in volunteers without migraine.
abstract: In this randomized, double-blind, three-period crossover trial, 24 healthy volunteers without migraine received zolmitriptan 5 mg, dexfenfluramine 15 mg or placebo orally. At 2, 6, and 24 h postdose, auditory stimuli of 1000 Hz (nontarget tone) and 2000 Hz (target tone) were randomly and binaurally presented in an active oddball paradigm (4:1 ratio). Cortical auditory evoked responses were recorded for 500 msec poststimulus. Plasma concentrations of zolmitriptan and a 17-lead quantitative EEG were assessed at the same timepoints. Relative to placebo, zolmitriptan reduced the maximum absolute amplitude, amplitude difference (from nontarget tone noise) and area under the curve of the cortical auditory target tone event-related potential (P300 ERP). The most dramatic effect of zolmitriptan was to diminish the point estimate of noise during the 200-400 msec poststimulus epoch. The effect of zolmitriptan appeared concentration dependent. The latency of the P300 ERP was unaffected by zolmitriptan and there was no clinically significant effect on the EEG. Modification by zolmitriptan of the cortical electrical activity evoked by auditory stimuli confirms a central action of this drug in humans, which appears to affect cortical information processing without global alteration of the quantitative EEG.
authors.affiliation: Zeneca Pharmaceuticals, Macclesfield, Cheshire, UK. Andrew.Hughes@Alderley.Zeneca.com
authors.forename: A M
authors.initials: AM
authors.lastname: Hughes
authors.forename: R
authors.initials: R
authors.lastname: Dixon
authors.forename: A
authors.initials: A
authors.lastname: Dane
authors.forename: J
authors.initials: J
authors.lastname: Kemp
authors.forename: L
authors.initials: L
authors.lastname: Cummings
authors.forename: R A
authors.initials: RA
authors.lastname: Yates
mesh_terms: D000161:Acoustic Stimulation; D000328:Adult; D004311:Double-Blind Method; D004569:Electroencephalography; D005072:Evoked Potentials, Auditory / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000503:physiopathology*; D010080:Oxazoles / Q000494:pharmacology*; D023303:Oxazolidinones; D012016:Reference Values; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*; D014363:Tryptamines
chemical_list: D010080:Oxazoles; D023303:Oxazolidinones; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C089750:zolmitriptan